Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 16/20 | 0.89 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.89 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887904 | 0.94 | P2RY2 (1.00) | P2RY2P2RY4NT5EGPR17 | |
| SCHEMBL6887907 | 0.85 | P2RY2 (0.83) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6399722 | 0.84 | P2RY2 (0.88) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6393343 | 0.79 | P2RY2 (1.00) | P2RY2P2RY4 | |
| SCHEMBL6886611 | 0.77 | P2RY2 (1.00) | P2RY2P2RY4 | |
| SCHEMBL6394295 | 0.76 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6400276 | 0.75 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6394660 | 0.74 | P2RY2 (0.63) | P2RY2P2RY4 | |
| SCHEMBL26887166 | 0.73 | P2RY2 (0.65) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6395428 | 0.72 | P2RY2 (1.00) | P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050142165-A1 | Implant device with a retinoid for improved biocompatibility | OLEJNIK OREST (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050009777-A1 | Non-natural carbon-linked nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| US-6743437-B2 | Implant device with a retinoid for improved biocompatibility | ALLERGAN, INC. | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009777-A1 | Non-natural carbon-linked nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | P2RY2 4/4885P2RY4 6/4885NT5E 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.